Refine your search

Search Results within category "Pain & Pain Management"

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

Search all categories

Suggestions within category "Pain & Pain Management"


5 Study Matches

Platelet-Rich Plasma Therapy for Patellar Tendinopathy (PRP)

The overall goal of this research is to find an effective treatment for patellar tendinopathy (PT). To achieve this, we will conduct a double-blinded randomized controlled trial to investigate if platelet-rich plasma is effective for treatment. Clinical (pain and function scores) and bio-mechanical (knee strength) measures will be correlated with disease modification changes assessed using conventional and novel quantitative magnetic resonance imaging (MRI) and ultrasound (US) techniques.
Kenneth Lee, M.D.
All
18 Years to 39 Years old
Phase 2
This study is NOT accepting healthy volunteers
NCT03136965
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
1. Age between 18 and 39 years 2. Chronic (>3 months) PT 3. Clinical examination consistent with PT 4. MRI or US confirmation of PT 5. Pain score of 3 or greater on a 10-point visual analogue scale 6. Self-report failure of supervised physical therapy 7. Self-report failure of at least 2 of the most common treatment options for PT (e.g. NSAIDs, relative rest, ice and bracing).
Exclusion Criteria:
1. Inability to comply with study follow-up requirements 2. History of bleeding disorders or other hematologic conditions 3. Knee pain from other possible etiologies (e.g., degenerative joint disease, meniscal tear, ligament injury or reconstruction) 4. Full or partial patellar tendon tear 5. Current use of anticoagulation or immunosuppressive therapy 6. Prior knee trauma requiring medical attention or surgery 7. Worker's compensation injury 8. Daily opioid use for pain 9. Contraindication to MRI. 10. Systemic diseases such as Diabetes and connective tissue diseases. 11. Prior PRP or DN procedure. 12. Women that are pregnant
Patellar Tendinitis, Musculoskeletal Abnormalities [C05], Patellar tendinitis, unspecified knee, Patellar tendinitis, right knee, Patellar tendinitis, left knee, Bone, Muscle & Joint, Pain & Pain Management
  Share Study Information
  Contact by Email
  Contact by Phone
  See more information

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) (POPS or POP02)

The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.
Maria Stanley
All
up to 20 Years old
NA
This study is also accepting healthy volunteers
NCT04278404
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
1. Participant is < 21 years of age 2. Parent/ Legal Guardian/ Adult Participant can understand the consent process and is willing to provide informed consent/HIPAA: 3. (a) Participant is receiving one or more of the study drugs of interest at the time of enrollment or (b) Participant is NOT receiving one or more of the study drugs of interest but is SARS-COV-2 positive within 60 days prior to enrollment
Exclusion Criteria:
1. Participant has a known pregnancy Below exclusion criteria apply only to participants receiving one or more of the study drugs of interest at the time of enrollment, 2. Has had intermittent dialysis within previous 24 hours 3. Has had a kidney transplant within previous 30 days 4. Has had a liver transplant within previous 1 year 5. Has had a stem cell transplant within previous 1 year 6. Has had therapeutic hypothermia within previous 24 hours 7. Has had plasmapheresis within the previous 24 hours 8. Has a Ventricular Assist Device 9. Has any condition which would make the participant, in the opinion of the investigator, unsuitable for the study
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis, Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
  Share Study Information
  Contact by Email
  See more information

Obstetric Liposomal Bupivacaine Via Surgical Transversus Abdominis Plane Block for Post Cesarean Pain Control (OBLiBupi)

This study seeks to identify whether the addition of liposomal bupivacaine to regular bupivacaine and saline administered via surgical transversus abdominis plane (TAP) block will reduce the cumulative opioid dose in the first 48 hours after cesarean. 60 women scheduled for cesarean at Unity-Point Health Meriter Hospital in Madison, Wisconsin will be enrolled and can be expect to be on study for up to 6 weeks post-partum.
Kathleen Antony, MD
Female
18 Years and over
Phase 4
This study is also accepting healthy volunteers
NCT04897841
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• Maternal age greater than or equal to 18
• Singleton or multifetal pregnancy
• Able to receive neuraxial analgesia
• Planned/ scheduled Cesarean delivery OR non-urgent Cesarean delivery at UnityPoint-Health Meriter with adequate time to consider and consent to the study
• Able to provide consent in English
Exclusion Criteria:

• Known hypersensitivity to bupivacaine or liposomal bupivacaine (defined as a history of a reaction or allergy to bupivacaine (injectable, intravenous, or transdermal) reported by patient or documented in the medical record) or patient report
• Plan by the obstetrical provider to inject bupivacaine or other local anesthetic into the cesarean incision due to potential differences in pain levels.
• Contraindication to regional analgesia
• Positive urine drug screen at admission to the hospital, if ordered for clinical purposes.
• Current opioid use or opioid use disorder per patient report or documented in the medical record or the Enhanced Prescription Drug Monitoring Program (ePDMP) (reviewed by Principal Investigator 1-14 days prior to surgery)
• Chronic opioid use or opioid use disorder, either patient reported or documented in the medical record or the ePDMP (reviewed by PI 1-14 days prior to surgery), defined as opioid use on most days for greater than 3 months
• Planned Cesarean hysterectomy (excluded due to anticipated blood loss and alternative pain control measures, possible prolonged intubation)
• Planned vertical midline incision
• Presence of renal dysfunction precluding the use of non-steroidal anti-inflammatory drugs (NSAIDs)
• Ischemic heart disease, congestive heart failure, or cardiomyopathy of pregnancy
• Coagulopathy
• Planned discharge from the hospital less than 48 hours postpartum
Pain, unspecified, Cesarean Section Complications, Pain, Opioid Use
  Share Study Information
  Contact by Email
  See more information

Pecto-Intercostal Fascial Plane Block Study

This study is being done to see if bilateral pecto-intercostal fascial plane blocks (PIFB) with a mixture of liposomal and standard bupivacaine decrease pain and opioid requirements in patients undergoing cardiac surgery via median sternotomy compared to controls (sham blocks with saline). 100 participants will be recruited and can expect to be on study for 100 days.
Pat Meyer
All
18 Years to 80 Years old
Phase 4
This study is NOT accepting healthy volunteers
NCT04928339
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• Participant provides consent to participate in study
• Ideal body weight (IBW) is >50kg
• Participant is planned to undergo coronary artery bypass graft or single valve repair/replacement surgery via median sternotomy
• Participant is undergoing an elective procedure
Exclusion Criteria:

• Participant is unable or unwilling to give consent
• Non-English speaking
• Known or believed to be pregnant or is currently breastfeeding
• Participant is a prisoner
• Clinically unstable per discretion of the Investigator
• Participant requires urgent/emergent surgery
• History of previous sternotomy
• Preoperative coagulopathy (INR >1.4, platelets <100,000) or ongoing anticoagulation or anti-platelet therapy (except aspirin 81mg)
• Allergy or sensitivity to amide-type local anesthetics, dexmedetomidine or ketamine
• Participant has decompensated heart failure
• Severe left ventricle dysfunction (defined quantitatively as an ejection fraction of less than or equal to 35%) or right ventricle dysfunction (defined qualitatively as "severe")
• Diagnosis of cirrhosis or end-stage liver disease
• Requires the use of mechanical circulatory support pre-operatively
• Participant uses chronic opioids (meaning at the time of the preoperative screening evaluation by the study team, the patient is prescribed and taking any opioid pain medication)
Cardiac Surgery, Opioid Use, Unspecified
  Share Study Information
  Contact by Email
  See more information

Visualizations to Improve Pain Communication Between Patients, Interpreters, and Providers

The purpose of this study is to pilot test a pain assessment information visualization (InfoViz) tool to facilitate communication about pain severity, location, and quality to increase mutual understanding between patients with limited English proficiency (LEP), interpreters, and providers during pain assessment. 40 participants will be enrolled and can expect to be on study for up to 4 weeks.
Maichou Lor
All
13 Years and over
N/A
This study is NOT accepting healthy volunteers
NCT04975789
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• age 18 and up
• Hmong patients that indicate they do not speak English well (LEP)
• self reported pain
Exclusion Criteria:

• indicate that they speak English well Interpreter
Inclusion Criteria:

• 13 years old or greater
• self-identify as interpreting for a Hmong individual in the health care setting Interpreter
Exclusion Criteria:

• telephone interpreters as they are unable to view and use the InfoViz tool
Communication, Pain, Pain, unspecified
  Share Study Information
  Contact by Email
  See more information